Cargando…

Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report

BACKGROUND: Glioblastoma (GBM) is a highly malignant brain neoplasm with poor survival. Despite its aggressive nature, metastatic spread of GBM is identified only rarely. While the molecular alterations associated with GBM and its subtypes are well-described, there remains a gap in understanding whi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Umphlett, Melissa, Shea, Stephanie, Tome-Garcia, Jessica, Zhang, Yizhou, Hormigo, Adilia, Fowkes, Mary, Tsankova, Nadejda M., Yong, Raymund L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971940/ https://www.ncbi.nlm.nih.gov/pubmed/31959133 http://dx.doi.org/10.1186/s12885-020-6540-1

Ejemplares similares

Tumoral and immune heterogeneity in an anti-PD-1-responsive glioblastoma: a case study
por: Restrepo, Paula, et al.
Publicado: (2020)

MRI Radiomic Features to Predict IDH1 Mutation Status in Gliomas: A Machine Learning Approach using Gradient Tree Boosting
por: Sakai, Yu, et al.
Publicado: (2020)

A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma
por: Chiu, Daniel, et al.
Publicado: (2023)

Prospective Isolation and Comparison of Human Germinal Matrix and Glioblastoma EGFR(+) Populations with Stem Cell Properties
por: Tome-Garcia, Jessica, et al.
Publicado: (2017)

The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy
por: Desland, Fiona A., et al.
Publicado: (2020)

The prognostic impact of subclonal IDH1 mutation in grade 2–4 astrocytomas
por: Vij, Meenakshi, et al.
Publicado: (2023)

Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma
por: Iwamoto, Fabio M., et al.
Publicado: (2014)

P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion in gliomas
por: Vij, Meenakshi, et al.
Publicado: (2023)

Multiparametric MRI texture analysis in prediction of glioma biomarker status: added value of MR diffusion
por: Kihira, Shingo, et al.
Publicado: (2021)

U-Net Based Segmentation and Characterization of Gliomas
por: Kihira, Shingo, et al.
Publicado: (2022)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Multi-Parametric Radiomic Model to Predict 1p/19q Co-Deletion in Patients with IDH-1 Mutant Glioma: Added Value to the T2-FLAIR Mismatch Sign
por: Kihira, Shingo, et al.
Publicado: (2023)

Exploiting the Complexities of Glioblastoma Stem Cells: Insights for Cancer Initiation and Therapeutic Targeting
por: Vieira de Castro, Joana, et al.
Publicado: (2020)

Analysis of chromatin accessibility uncovers TEAD1 as a regulator of migration in human glioblastoma
por: Tome-Garcia, Jessica, et al.
Publicado: (2018)

IDH-mutant astrocytoma with EGFR amplification—Genomic profiling in four cases and review of literature
por: Umphlett, Melissa, et al.
Publicado: (2022)

Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment
por: Tejero, Rut, et al.
Publicado: (2019)

Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1
por: Gallitto, Matthew, et al.
Publicado: (2020)

BRCA1 germline mutation and glioblastoma development: report of cases
por: Boukerroucha, Meriem, et al.
Publicado: (2015)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018)

Genome-Wide Gene Expression Analyses of BRCA1- and BRCA2-Associated Breast and Ovarian Tumours
por: Wiggins, George A. R., et al.
Publicado: (2020)

ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target
por: Cheng, Xuan, et al.
Publicado: (2021)

Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement
por: Connelly, Jennifer, et al.
Publicado: (2016)

ARID1B is a specific vulnerability in ARID1A-mutant cancers
por: Helming, Katherine C., et al.
Publicado: (2014)

Prominin 1/CD133 Endothelium Sustains Growth of Proneural Glioma
por: Ding, Bi-Sen, et al.
Publicado: (2013)

51. BRAIN METASTASES FROM ENDOMETRIAL CARCINOMA: TUMOR GENETIC ALTERATIONS IN A CASE SERIES AND META-ANALYSIS
por: Chapman, Emily K, et al.
Publicado: (2020)

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
por: Abida, Wassim, et al.
Publicado: (2020)

Federated analysis of BRCA1 and BRCA2 variation in a Japanese cohort
por: Casaletto, James, et al.
Publicado: (2022)

Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer
por: Santivasi, W L, et al.
Publicado: (2015)

Systematic misclassification of missense variants in BRCA1 and BRCA2 “coldspots”
por: Dines, Jennifer N., et al.
Publicado: (2020)

A paracrine circuit of IL-1β/IL-1R1 between myeloid and tumor cells drives genotype-dependent glioblastoma progression
por: Chen, Zhihong, et al.
Publicado: (2023)

Genome-wide RNAi to identify genes that confer synthetic lethality with BRCA1
por: Petalcorin, MIR, et al.
Publicado: (2006)

Comparative genomic analysis of driver mutations in matched primary and recurrent meningiomas
por: Loewenstern, Joshua, et al.
Publicado: (2019)

Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma
por: Sausen, Mark, et al.
Publicado: (2012)

Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers
por: Khalique, Saira, et al.
Publicado: (2018)

BK virus encephalopathy and sclerosing vasculopathy in a patient with hypohidrotic ectodermal dysplasia and immunodeficiency
por: Darbinyan, Armine, et al.
Publicado: (2016)

Roles of the PARP Inhibitor in BRCA1 and BRCA2 Pathogenic Mutated Metastatic Prostate Cancer: Direct Functions and Modification of the Tumor Microenvironment
por: Inoue, Takahiro, et al.
Publicado: (2023)

ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer
por: Zhu, Guangsheng, et al.
Publicado: (2021)

Consistency of BRCA1 and BRCA2 Variant Classifications Among Clinical Diagnostic Laboratories
por: Lincoln, Stephen E., et al.
Publicado: (2017)

Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity
por: Sokol, Ethan S., et al.
Publicado: (2020)

ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma
por: Sato, Emi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4qo4b314h9hqfod9u1age9jk45